Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765277 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL8275384 | 0.78 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL28428414 | 0.77 | CHRM2 (0.55) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL5954654 | 0.74 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL17749939 | 0.74 | ALDH1A1 (0.44) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL4723565 | 0.73 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL14377332 | 0.73 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL14811086 | 0.73 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2913826 | 0.73 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL18660627 | 0.73 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025126115-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-19 | — | — | WO | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2024033280-A1 | FUROPYRIDIN AND FUROPYRIMIDIN, INHIBITORS OF PI4K, FOR USE IN THE TREATMENT OF PARASITE INFECTION AND MALARIA | MERCK PATENT GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | TLL Pharmaceutical, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | HANGZHOU HIGHLIGHTII PHARMACEUTICAL CO., LTD (CN) | 2019-08-22 | — | — | US | disclosed |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| WO-2013117285-A1 | FURO [3, 2 - B] - AND THIENO [3, 2 - B] PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-15 | — | — | WO | disclosed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | CHRNB2 3606/4885CHRNA4 4139/4885CHRM2 1395/4885 |
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | JAK1, JAK3, JAK2 | CHRNB2 4867/4885CHRNA4 4836/4885CHRM2 4879/4885 |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | CHRNB2 3111/4885CHRNA4 3885/4885CHRM2 4598/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | CHRNB2 3606/4885CHRNA4 4139/4885CHRM2 1395/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | CHRNB2 3464/4885CHRNA4 4168/4885CHRM2 3029/4885 |
| US-20190256523-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | JAK1, JAK3, JAK2 | CHRNB2 4861/4885CHRNA4 4835/4885CHRM2 4876/4885 |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | CHRNB2 3111/4885CHRNA4 3885/4885CHRM2 4598/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | CHRNB2 3606/4885CHRNA4 4139/4885CHRM2 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.